Literature DB >> 7969976

Late-onset riboflavin-responsive myopathy with combined multiple acyl coenzyme A dehydrogenase and respiratory chain deficiency.

C Antozzi1, B Garavaglia, M Mora, M Rimoldi, L Morandi, E Ursino, S DiDonato.   

Abstract

We studied the effect of riboflavin treatment on the clinical status and on the activities of beta-oxidation and respiratory chain enzymes in a 69-year-old patient with late-onset myopathy. Before treatment, she was very weak and wasted in the limbs and trunk muscles; also, she could not walk or attend to daily activities. Marked lipid storage was present in the muscle biopsy. The activities of short-chain acyl coenzyme A (acyl-CoA) dehydrogenase (SCAD), medium-chain acyl-CoA dehydrogenase (MCAD), and long-chain acyl-CoA dehydrogenase (LCAD) in isolated muscle mitochondria were reduced to less than 10% of control values. This defect in fatty acid oxidation was associated with a marked deficiency of two flavin-dependent respiratory chain complexes: complex I activity was 20% and complex II activity was 25% of control values. By contrast, the activities of the nonflavin-dependent complex III and complex IV were normal. Western blot analysis of the patient's muscle mitochondrial extracts with antibodies raised against purified SCAD, MCAD, and the alpha- and beta-subunits of the electron transfer flavoprotein (ETF) showed absence of SCAD cross-reacting material (CRM), markedly decreased MCAD-CRM, and normal amounts of both alpha- and beta-ETF-CRM. After riboflavin treatment, the patient's clinical status dramatically improved and morphologic changes in muscle disappeared. SCAD activity increased to 55% of control values, whereas MCAD, LCAD, and complex I and complex II activities normalized. SCAD and MCAD immunoreactivity was restored to normal. On the basis of our experience and the data in the literature, we concluded that some lipid storage myopathies can show dramatic response to riboflavin.

Entities:  

Mesh:

Substances:

Year:  1994        PMID: 7969976     DOI: 10.1212/wnl.44.11.2153

Source DB:  PubMed          Journal:  Neurology        ISSN: 0028-3878            Impact factor:   9.910


  14 in total

Review 1.  Lipid storage myopathy.

Authors:  Wen-Chen Liang; Ichizo Nishino
Journal:  Curr Neurol Neurosci Rep       Date:  2011-02       Impact factor: 5.081

2.  Riboflavin and migraine: the bridge over troubled mitochondria.

Authors:  Bruno Colombo; Lorenzo Saraceno; Giancarlo Comi
Journal:  Neurol Sci       Date:  2014-05       Impact factor: 3.307

3.  Comment on: "Multiple acyl‑CoA dehydrogenase deficiency in elderly carriers".

Authors:  Yılmaz Yıldız; Ayşegül Tokatlı
Journal:  J Neurol       Date:  2020-02-12       Impact factor: 4.849

4.  Lipid-storage myopathy and respiratory insufficiency due to ETFQO mutations in a patient with late-onset multiple acyl-CoA dehydrogenation deficiency.

Authors:  R K J Olsen; M Pourfarzam; A A M Morris; R C Dias; I Knudsen; B S Andresen; N Gregersen; S E Olpin
Journal:  J Inherit Metab Dis       Date:  2004       Impact factor: 4.982

5.  Gametocytocidal activity and synergistic interactions of riboflavin with standard antimalarial drugs against growth of Plasmodium falciparum in vitro.

Authors:  T Akompong; S Eksi; K Williamson; K Haldar
Journal:  Antimicrob Agents Chemother       Date:  2000-11       Impact factor: 5.191

6.  Flavin adenine dinucleotide rescues the phenotype of frataxin deficiency.

Authors:  Pilar Gonzalez-Cabo; Sheila Ros; Francesc Palau
Journal:  PLoS One       Date:  2010-01-25       Impact factor: 3.240

7.  Riboflavin prophylaxis in pediatric and adolescent migraine.

Authors:  Maria Condò; Annio Posar; Annalisa Arbizzani; Antonia Parmeggiani
Journal:  J Headache Pain       Date:  2009-08-01       Impact factor: 7.277

Review 8.  Evidence that Oxidative Disbalance and Mitochondrial Dysfunction are Involved in the Pathophysiology of Fatty Acid Oxidation Disorders.

Authors:  Graziela Schmitt Ribas; Carmen Regla Vargas
Journal:  Cell Mol Neurobiol       Date:  2020-09-02       Impact factor: 5.046

Review 9.  The biochemical and cellular basis for nutraceutical strategies to attenuate neurodegeneration in Parkinson's disease.

Authors:  Elizabeth A Mazzio; Fran Close; Karam F A Soliman
Journal:  Int J Mol Sci       Date:  2011-01-17       Impact factor: 5.923

Review 10.  State of the art in muscle lipid diseases.

Authors:  W C Liang; I Nishino
Journal:  Acta Myol       Date:  2010-10
View more

北京卡尤迪生物科技股份有限公司 © 2022-2023.